8 results match your criteria: "USA National Institute on Drug Abuse[Affiliation]"
How Pain-Related Facial Expressions Are Evaluated in Relation to Gender, Race, and Emotion.
Affect Sci
June 2023
10, Center Drive, Bethesda, MD 20892 USA National Center for Complementary and Integrative Health, National Institutes of Health.
Unlabelled: Inequities in pain assessment are well-documented; however, the psychological mechanisms underlying such biases are poorly understood. We investigated potential perceptual biases in the judgments of faces displaying pain-related movements. Across five online studies, 956 adult participants viewed images of computer-generated faces ("targets") that varied in features related to race (Black and White) and gender (women and men).
View Article and Find Full Text PDFHigh-Resolution Functional Connectivity Density: Hub Locations, Sensitivity, Specificity, Reproducibility, and Reliability.
Cereb Cortex
July 2016
National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA National Institute on Drug Abuse, Bethesda, MD, USA.
Brain regions with high connectivity have high metabolic cost and their disruption is associated with neuropsychiatric disorders. Prior neuroimaging studies have identified at the group-level local functional connectivity density ( L: FCD) hubs, network nodes with high degree of connectivity with neighboring regions, in occipito-parietal cortices. However, the individual patterns and the precision for the location of the hubs were limited by the restricted spatiotemporal resolution of the magnetic resonance imaging (MRI) measures collected at rest.
View Article and Find Full Text PDFDissecting Neural Responses to Temporal Prediction, Attention, and Memory: Effects of Reward Learning and Interoception on Time Perception.
Cereb Cortex
October 2015
National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD 20892, USA National Institute on Drug Abuse, Bethesda, MD 20892, USA.
Temporal prediction (TP) is needed to anticipate future events and is essential for survival. Our sense of time is modulated by emotional and interoceptive (corporal) states that are hypothesized to rely on a dopamine (DA)-modulated "internal clock" in the basal ganglia. However, the neurobiological substrates for TP in the human brain have not been identified.
View Article and Find Full Text PDFBaclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety.
Alcohol Alcohol
November 2014
NHMRC Centre of Research Excellence in Mental Health and Substance Use, Discipline of Addiction Medicine, University of Sydney, Sydney, NSW, Australia Drug Health Services, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Aim: To conduct a double-blind, placebo-controlled randomized clinical trial of baclofen in the treatment of alcohol dependence.
Methods: Out of 69 participants consecutively screened, 42 alcohol-dependent patients were randomized to receive placebo, baclofen 30 mg/day or baclofen 60 mg/day for 12 weeks. All subjects were offered BRENDA, a structured psychosocial therapy for alcohol dependence that seeks to improve motivation for change, enhance strategies to prevent relapse and encourage compliance with treatment.
Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations.
Pain
November 2013
Department of Medicine, University of Rochester, Rochester, NY, USA Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, USA Department of Anesthesiology, University of Rochester, Rochester, NY, USA Analgesic Solutions, Natick, MA, USA Department of Anesthesiology, Tufts University School of Medicine, Boston, MA, USA Colucci & Associates LLC, Newtown, CT, USA Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA United States Food and Drug Administration, Silver Spring, MD, USA Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA Center for Suicide Risk Assessment, New York State Psychiatric Institute/College of Physicians and Surgeons, Columbia University, New York, NY, USA Department of Psychiatry, University of Florida College of Medicine, Gainesville, FL, USA Covance, Princeton, NJ, USA Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, USA American Chronic Pain Association, Rocklin, CA, USA National Institute on Drug Abuse, Rockville, MD, USA Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA Purdue Pharma LP, Stamford, CT, USA Department of Public Health & Community Medicine, Tufts University School of Medicine, Boston, MA, USA Pfizer Inc, Ann Arbor, MI, USA Eisai Limited, Woodcliff Lake, NJ, USA Endo Pharmaceuticals Inc, Chadds Ford, PA, USA CNS Drug Consulting LLC, McLean, VA, USA Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY, USA AcelRx Pharmaceuticals Inc, Redwood City, CA, USA Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore School of Medicine, MD, USA Johnson & Johnson Pharmaceutical Research & Development LLC, Raritan, NJ, USA California Pacific Medical Center Research Institute, San Francisco, CA, USA Clinical Pharmacology and Therapeutics Laboratory, Faculdade de Medicina de Lisboa, Lisbon, Portugal King Pharmaceuticals Inc, Cary, NC, USA Grünenthal USA Inc, Bedminster, NJ, USA Durect Corporation, Cupertino, CA, USA Department of Behavioral Science, Center on Drug and Alcohol Research, University of Kentucky, KY, USA Department of Anesthesia & Critical Care, University of Chicago, Chicago, IL, USA.
Assessing and mitigating the abuse liability (AL) of analgesics is an urgent clinical and societal problem. Analgesics have traditionally been assessed in randomized clinical trials (RCTs) designed to demonstrate analgesic efficacy relative to placebo or an active comparator. In these trials, rigorous, prospectively designed assessment for AL is generally not performed.
View Article and Find Full Text PDFClassification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations.
Pain
November 2013
Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA University of Colorado School of Medicine and Rocky Mountain Poison & Drug Center, Denver Health, Denver, CO, USA Analgesic Solutions, Natick, MA, USA Tufts University, Boston, MA, USA Focus Biocom, Durango, CO, USA Covance Market Access, Gaithersburg, MD, USA Columbia University, New York State Psychiatric Institute, New York, NY, USA Astellas Pharma, Inc., Northbrook, IL, USA Brigham & Women's Hospital, Boston, MA, USA Purdue Pharma LP, Stamford, CT, USA University of Maryland School of Medicine, Baltimore, MD, USA Centers for Disease Control and Prevention, Atlanta, GA, USA Collegium Pharmaceutical, Inc., Canton, MA, USA Department of Neurosurgery, University of Rochester, Rochester, NY, USA National Institute on Drug Abuse, Bethesda, MD, USA University of Pennsylvania, Philadelphia, PA, USA Pfizer Inc., Cary, NC, USA Horizon Pharma, Inc., Deerfield, IL, USA Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA Janssen Scientific Affairs, LLC, Raritan, NJ, USA Harvard Medical School, Chestnut Hill, MA, USA Harvard Medical School, Boston, MA, USA Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA, USA Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, USA Department of Neurology and Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
As the nontherapeutic use of prescription medications escalates, serious associated consequences have also increased. This makes it essential to estimate misuse, abuse, and related events (MAREs) in the development and postmarketing adverse event surveillance and monitoring of prescription drugs accurately. However, classifications and definitions to describe prescription drug MAREs differ depending on the purpose of the classification system, may apply to single events or ongoing patterns of inappropriate use, and are not standardized or systematically employed, thereby complicating the ability to assess MARE occurrence adequately.
View Article and Find Full Text PDFFunctional connectivity and brain activation: a synergistic approach.
Cereb Cortex
October 2014
National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA National Institute on Drug Abuse, Bethesda, MD, USA.
Traditional functional magnetic resonance imaging (fMRI) studies exploit endogenous brain activity for mapping brain activation during "periodic" cognitive/emotional challenges or brain functional connectivity during the "resting state". Previous studies demonstrated that these approaches provide a limited view of brain function which can be complemented by each other. We hypothesized that graph theory functional connectivity density (FCD) mapping would demonstrate regional FCD decreases between resting-state scan and a continuous "task-state" scan.
View Article and Find Full Text PDFResearch design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations.
Pain
October 2012
University of Washington, Seattle, Washington, USA University of Rochester, Rochester, New York, USA Johns Hopkins University, Baltimore, Maryland, USA Analgesic Solutions and Tufts University, Boston, Massachusetts, USA Covance, Conshohocken, Pennsylvania, USA Harvard Medical School, Boston, Massachusetts, USA Columbia University, New York, USA Denver Health Authority and Rocky Mountain Poison and Drug Center, Denver, Colorado, USA University of North Carolina, Chapel Hill, North Carolina, USA National Institute on Drug Abuse, Bethesda, Maryland, USA United States Food and Drug Administration, Silver Spring, Maryland, USA CNS Drug Consulting, McLean, Virginia, USA University of Chicago, Chicago, Illinois, USA Endo Pharmaceuticals, Chadds Ford, Pennsylvania, USA American Chronic Pain Association, Rocklin, California, USA AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA Brigham and Women's Hospital, Boston, Massachusetts, USA AcelRx Pharmaceuticals, Redwood City, California, USA University of Texas Health Science Center San Antonio, San Antonio, Texas, USA Johnson & Johnson Pharmaceutical Research & Development, Titusville, New Jersey, USA Pfizer, New Brunswick, New Jersey, USA Clinical Research and Pain Clinic, Salt Lake City, Utah, USA NAMA Recovery, Cedar Park, Texas, USA.
Opioids are essential to the management of pain in many patients, but they also are associated with potential risks for abuse, overdose, and diversion. A number of efforts have been devoted to the development of abuse-deterrent formulations of opioids to reduce these risks. This article summarizes a consensus meeting that was organized to propose recommendations for the types of clinical studies that can be used to assess the abuse deterrence of different opioid formulations.
View Article and Find Full Text PDF